ARMP on NYSE
Armata Pharmaceuticals, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Grant and award revenue | $4.9M | $5.2M |
| Research and development | $23.7M | $34.4M |
| General and administrative | $12.4M | $13.2M |
| Impairment expense | $5.4M | |
| Total operating expenses | $41.5M | $47.6M |
| Operating loss | -$36.6M | -$42.4M |
| Interest income | $388.0K | $697.0K |
| Interest expense | -$16.6M | -$10.7M |
| Change in fair value of the Convertible Loan | -$121.0M | $31.4M |
| Gain on debt and the Convertible Loan extinguishments | $2.2M | |
| Total other income (expense), net | -$137.2M | $23.5M |
| Net loss | -$173.8M | -$18.9M |
| Net loss per share, basic | -$4.80 | -$0.52 |
| Weighted average shares outstanding, basic | 36.2M shares | 36.2M shares |
| Net loss per share, diluted | -$4.80 | -$0.89 |
| Weighted average shares outstanding, diluted | 36.2M shares | 59.1M shares |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $8.7M | $9.3M | |
| Prepaid expenses and other current assets | $1.5M | $1.3M | |
| Other receivables | $472.0K | $744.0K | |
| Total current assets | $10.7M | $11.3M | |
| Restricted cash | $5.4M | $5.5M | |
| Property and equipment, net | $12.2M | $13.2M | |
| Operating lease right-of-use asset | $33.9M | $41.7M | |
| In-process research and development | $10.3M | $10.3M | |
| Goodwill | $3.5M | $3.5M | |
| Other assets | $973.0K | $975.0K | |
| Total assets | $76.9M | $86.4M | |
| Accounts payable and accrued liabilities | $1.7M | $2.1M | |
| Accrued compensation | $2.2M | $2.3M | |
| Term debt, current | $39.0M | ||
| Current portion of operating lease liabilities | $4.6M | $4.4M | |
| Other current liabilities | $487.0K | $529.0K | |
| Total current liabilities | $8.9M | $48.2M | |
| Convertible Loan, non-current | $153.9M | $32.9M | |
| Term debt, non-current | $103.1M | $22.5M | |
| Operating lease liabilities, net of current portion | $26.5M | $27.7M | |
| Deferred tax liability | $3.1M | $3.1M | |
| Total liabilities | $295.5M | $134.5M | |
| Common Stock, $0.01 par value; 217,000,000 shares authorized; 36,431,444 and 36,183,067 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $364.0K | $362.0K | |
| Additional paid-in capital | $282.6M | $279.4M | |
| Accumulated deficit | -$501.5M | -$327.7M | |
| Total stockholders' deficit | -$218.6M | -$48.0M | -$32.1M |
| Total liabilities and stockholders' deficit | $76.9M | $86.4M | |
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Common stock, shares authorized | 217.0M shares | 217.0M shares | |
| Common stock, shares issued | 36.4M shares | 36.2M shares | |
| Common stock, shares outstanding | 36.4M shares | 36.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$173.8M | -$18.9M |
| Depreciation expense | $1.5M | $1.3M |
| Stock-based compensation expense | $2.6M | $2.9M |
| Change in fair value of the Convertible Loan | $121.0M | -$31.4M |
| Non-cash interest expense | $16.6M | $10.8M |
| Gain on debt and Convertible Loan extinguishments | -$2.2M | |
| Impairment expense | $5.4M | |
| Change in right-of-use asset | $2.4M | $2.1M |
| Prepaid expenses and other assets | $39.0K | $5.1M |
| Accounts payable and accrued liabilities | -$334.0K | -$3.8M |
| Accrued compensation | -$89.0K | $1.5M |
| Operating lease liability | -$1.0M | -$5.0M |
| Net cash used in operating activities | -$25.8M | -$37.6M |
| Purchases of property and equipment | -$542.0K | -$1.9M |
| Net cash used in investing activities | -$542.0K | -$1.9M |
| Proceeds from issuance of term debt, net of issuance costs | $25.0M | $34.9M |
| Payments for taxes related to net share settlement of equity awards | -$46.0K | -$61.0K |
| Proceeds from exercise of stock options | $658.0K | $130.0K |
| Net cash provided by financing activities | $25.6M | $35.0M |
| Net change in cash, cash equivalents and restricted cash | -$693.0K | -$4.5M |
| Right-of-use asset obtained by assuming operating lease liabilities | $977.0K |
Former names
Recent filings
- Sep 23, 20268-K
- Sep 14, 20268-K
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Jul 20, 20268-K
- Jul 20, 20268-K
- Jul 14, 20264 OWNERSHIP DOCUMENT
- Jul 13, 2026S-8
- Jul 13, 20268-K
- Jun 24, 20268-K/A
- Jun 23, 20268-K
- Jun 16, 20268-K
- May 13, 20268-K
- May 13, 202610-Q
- May 7, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10